GC Genome targets FDA application this year for Panc Sight pancreatic cancer test
AI Summary- GC Genome is pursuing U.S. market entry for its Panc Sight test.
- GC Genome aims to file a formal FDA application within the year.
- The company targets U.S. clearance by mid-next year.